Health department sets up cost sharing deal for multiple myeloma drugBMJ 2009; 338 doi: http://dx.doi.org/10.1136/bmj.b423 (Published 02 February 2009) Cite this as: BMJ 2009;338:b423
- Clare Dyer
People in England and Wales with multiple myeloma are expected to get access to the life extending drug lenalidomide (Revlimid) on the NHS after the National Institute for Health and Clinical Excellence (NICE) struck a deal with its manufacturer.
NICE, which had previously decided against approving the drug because of concerns about cost effectiveness, has overturned its own preliminary recommendation and approved lenalidomide in combination with dexamethasone for patients who have already tried two or more drugs.
The new guidance is …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial